Business, energy, technology, markets and global industry news from Business News Today

ObesityWeek

PharmaDeviceNews ObesityWeek
Representative image: Oral metabolic drug research illustrates Novo Nordisk’s $2.6 billion Hengrui deal for once-weekly GLP-1/GIP candidate HRS-1596 in obesity and diabetes.
Pharma & Biotech

Mitotech is testing a different way to burn fat. Could MT-1101 complement GLP-1 drugs?

Mitotech will present MT-1101 obesity data comparing its mitochondrial approach with semaglutide. See what preclinical results could mean for development.

Read More
Khondrion Phase 3 KHENERFIN study of sonlicromanol in m.3243A>G primary mitochondrial disease, a representative image of rare disease drug development and mitochondrial therapy research.
Pharma & Biotech

Cambrian Bio’s ATX-304 raised resting metabolic rate by up to 33%. Could obesity treatment move beyond appetite suppression?

Cambrian Bio will present new ATX-304 metabolic data at ObesityWeek 2026. See how AMPK activation could influence future obesity treatment.

Read More